Why I changed my mind about the dead donor rule

By Lawrence Masek Must organ transplant teams wait until a potential donor dies before removing a vital organ? I used to answer yes, because removing a vital organ from a living donor seemed intuitively wrong, and I assumed that anyone who answered no either accepted a consequentialist view of organ transplants or denied that potential […]

Read More…

Thoraco-Abdominal Normothermic Regional Perfusion: Can the dead “beheaded” donor be killed?

By Christos Lazaridis. Thoraco-abdominal normothermic regional perfusion (TA-NRP) is a relatively novel technique for donation after the circulatory determination of death (DCDD). In short, after declaration of death by circulatory criteria (as in conventional DCDD), the circulation to the brain is surgically excluded followed by extracorporeal membrane oxygenation (ECMO) and perfusion of the thoracoabdominal organs. […]

Read More…

Respecting and learning from the dead: Ethical research involving the recently deceased

By Brendan Parent, Mary Homan, Olivia Kates, Wadih Arap, Brian Childs, and Kathy Kinlaw. Our bodies can have value after our death. Organs can be donated to save multiple lives through transplantation. Preserved cadavers or body parts may contribute to medical education to prepare future physicians to practice medicine on the living. Dead bodies can […]

Read More…

Should AI allocate livers for transplant?

By Max Drezga-Kleiminger, Joanna Demaree-Cotton, Julian Koplin, Julian Savulescu, and Dominic Wilkinson. The field of artificial intelligence (AI) is moving rapidly. In the (recent) past, we could hide behind the knowledge that much of the ethical discourse around AI was in hypothetical terms – we were discussing what we should do in case technology progressed […]

Read More…

Response to Nix and Weijer: Close Eneph? SARS-CoV-2 challenge studies and altruistic kidney donation

By Abie Rohrig and David Manheim. In a recent blog post, Nix and Weijer argue that living kidney donation and volunteering for a COVID-19 challenge trial are disanalogous, and that “advocates of SARS-CoV-2 challenge studies must look elsewhere to justify the level of risk in these studies.” They offer three arguments to support this view: adverse effects […]

Read More…